Pentapeptide amides interfere with the aggregation of β-amyloid peptide of Alzheimer's disease

C. Hetényi, Zoltán Szabó, E. Klement, Zsolt Datki, T. Körtvélyesi, Márta Zarándi, B. Penke

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Amyloid peptides (Aβ) play a central role in the pathogenesis of Alzheimer's disease (AD). The aggregation of Aβ molecules leads to fibril and plaque formation. Fibrillogenesis is at the same time a marker and an indirect cause of AD. Inhibition of the aggregation of Aβ could be a realistic therapy for the illness. Beta sheet breakers (BSBs) are one type of fibrillogenesis inhibitors. The first BSB peptides were designed by Tjernberg et al. (1996) and Soto et al. (1998). These pentapeptides have proved their efficiency in vitro and in vivo. In the present study, the effects of two pentapeptide amides are reported. These compounds were designed by using the C-terminal sequence of the amyloid peptide as a template. Biological assays were applied to demonstrate efficiency. Modes of action were studied by FT-IR spectroscopy and molecular modeling methods.

Original languageEnglish
Pages (from-to)931-936
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume292
Issue number4
DOIs
Publication statusPublished - 2002

Fingerprint

Amyloid
Amides
Alzheimer Disease
Agglomeration
Efficiency
Peptides
Molecular modeling
Biological Assay
Infrared spectroscopy
Assays
Spectrum Analysis
Molecules
beta-Strand Protein Conformation
Therapeutics
In Vitro Techniques
Inhibition (Psychology)
peptide A

Keywords

  • β sheet breaker
  • Aggregation
  • Amyloid fragments
  • Docking
  • Fibril
  • Inhibitor
  • Neurotoxicity

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Pentapeptide amides interfere with the aggregation of β-amyloid peptide of Alzheimer's disease. / Hetényi, C.; Szabó, Zoltán; Klement, E.; Datki, Zsolt; Körtvélyesi, T.; Zarándi, Márta; Penke, B.

In: Biochemical and Biophysical Research Communications, Vol. 292, No. 4, 2002, p. 931-936.

Research output: Contribution to journalArticle

@article{2da5cdd57fca446da63a616207815889,
title = "Pentapeptide amides interfere with the aggregation of β-amyloid peptide of Alzheimer's disease",
abstract = "Amyloid peptides (Aβ) play a central role in the pathogenesis of Alzheimer's disease (AD). The aggregation of Aβ molecules leads to fibril and plaque formation. Fibrillogenesis is at the same time a marker and an indirect cause of AD. Inhibition of the aggregation of Aβ could be a realistic therapy for the illness. Beta sheet breakers (BSBs) are one type of fibrillogenesis inhibitors. The first BSB peptides were designed by Tjernberg et al. (1996) and Soto et al. (1998). These pentapeptides have proved their efficiency in vitro and in vivo. In the present study, the effects of two pentapeptide amides are reported. These compounds were designed by using the C-terminal sequence of the amyloid peptide as a template. Biological assays were applied to demonstrate efficiency. Modes of action were studied by FT-IR spectroscopy and molecular modeling methods.",
keywords = "β sheet breaker, Aggregation, Amyloid fragments, Docking, Fibril, Inhibitor, Neurotoxicity",
author = "C. Het{\'e}nyi and Zolt{\'a}n Szab{\'o} and E. Klement and Zsolt Datki and T. K{\"o}rtv{\'e}lyesi and M{\'a}rta Zar{\'a}ndi and B. Penke",
year = "2002",
doi = "10.1006/bbrc.2002.6745",
language = "English",
volume = "292",
pages = "931--936",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Pentapeptide amides interfere with the aggregation of β-amyloid peptide of Alzheimer's disease

AU - Hetényi, C.

AU - Szabó, Zoltán

AU - Klement, E.

AU - Datki, Zsolt

AU - Körtvélyesi, T.

AU - Zarándi, Márta

AU - Penke, B.

PY - 2002

Y1 - 2002

N2 - Amyloid peptides (Aβ) play a central role in the pathogenesis of Alzheimer's disease (AD). The aggregation of Aβ molecules leads to fibril and plaque formation. Fibrillogenesis is at the same time a marker and an indirect cause of AD. Inhibition of the aggregation of Aβ could be a realistic therapy for the illness. Beta sheet breakers (BSBs) are one type of fibrillogenesis inhibitors. The first BSB peptides were designed by Tjernberg et al. (1996) and Soto et al. (1998). These pentapeptides have proved their efficiency in vitro and in vivo. In the present study, the effects of two pentapeptide amides are reported. These compounds were designed by using the C-terminal sequence of the amyloid peptide as a template. Biological assays were applied to demonstrate efficiency. Modes of action were studied by FT-IR spectroscopy and molecular modeling methods.

AB - Amyloid peptides (Aβ) play a central role in the pathogenesis of Alzheimer's disease (AD). The aggregation of Aβ molecules leads to fibril and plaque formation. Fibrillogenesis is at the same time a marker and an indirect cause of AD. Inhibition of the aggregation of Aβ could be a realistic therapy for the illness. Beta sheet breakers (BSBs) are one type of fibrillogenesis inhibitors. The first BSB peptides were designed by Tjernberg et al. (1996) and Soto et al. (1998). These pentapeptides have proved their efficiency in vitro and in vivo. In the present study, the effects of two pentapeptide amides are reported. These compounds were designed by using the C-terminal sequence of the amyloid peptide as a template. Biological assays were applied to demonstrate efficiency. Modes of action were studied by FT-IR spectroscopy and molecular modeling methods.

KW - β sheet breaker

KW - Aggregation

KW - Amyloid fragments

KW - Docking

KW - Fibril

KW - Inhibitor

KW - Neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=0036293083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036293083&partnerID=8YFLogxK

U2 - 10.1006/bbrc.2002.6745

DO - 10.1006/bbrc.2002.6745

M3 - Article

C2 - 11944904

AN - SCOPUS:0036293083

VL - 292

SP - 931

EP - 936

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -